Hypertension grade ≥ 3 · newly‐diagnosed EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hypertension (grade ≥ 2) · platinum‐sensitive recurrent EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hypertension (grade ≥ 2) · platinum‐sensitive recurrent EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hypertension (grade ≥ 2) · recurrent platinum‐resistant EOC
Chemotherapy with bevacizumab may leads to higher hypertension (grade ≥ 2) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Hypertension (grade ≥ 2)Â · recurrent platinum‐resistant EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hypertension (grade ≥ 2)Â · recurrent EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hypertension (grade ≥ 2) · newly‐diagnosed EOC
Chemotherapy with bevacizumab followed by maintenance bevacizumab may leads to higher hypertension (grade ≥ 2) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Pain intensity various scales short‐term · patients with non‐specific acute and subacute low back pain
1 finding from 1 review
Pain intensity various scales short‐term · patients with non‐specific acute and subacute low back pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain: intermediate‐term · patients with non‐specific acute and subacute low back pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain: intermediate‐term · patients with non‐specific acute and subacute low back pain
1 finding from 1 review
Pain intensity various scales short‐term · patients with non‐specific acute and subacute low back pain
1 finding from 1 review
Pain: intermediate‐term · patients with non‐specific acute and subacute low back pain
1 finding from 1 review
Intensity of disease signs and symptoms1 · people with non‐ulcerated chronic venous insufficiency
It is very uncertain whether physical exercise changes intensity of disease signs and symptoms: VCSS Scale: 0 to 30 (lower… compared with no treatment (very low certainty).
1 finding from 1 review
ICU length of stay (selenium) · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
ICU length of stay (general intensive care patients) · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
New or enlarging T2‐hyperintense lesions · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
The review found no eligible studies for this question.
1 finding from 1 review
Number of participants with new or enlarging T2‐hyperintense lesions on MRI · adults with relapsing–remitting multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Hypertensive disorders of pregnancy · pregnant women (women with pre‐existing type 1 or type 2 diabetes are NOT included)
The intervention may leads to lower hypertensive disorders of pregnancy (low certainty).
1 finding from 1 review
Intervention not reported
Pain intensity measured on CHQ (0‐100; 0 = worse pain), and VAS (0 to 100; 0 = no pain) Postintervention: first assessment after end of treatment; no later than 3 months · children and adolescents aged 4 years to 18 years, with chronic musculoskeletal pain
1 finding from 1 review